MK-0518
From Wikipedia, the free encyclopedia
MK-0518 (generic name raltegravir; Brand name IsentressTM) is an experimental antiretroviral drug from Merck & Co. It is the first to enter Phase III clinical trials in the integrase inhibitor class. It targets integrase, an enzyme that HIV uses to integrate its genetic material into human cells.
During 2006, the drug entered Phase III clinical trials, and it is available to certain patients with advanced HIV disease through an expanded access program. [1]
MK-0518 is taken orally twice daily. Doses of 200, 400, and 600 mg have been studied.
At the 2007 Conference on Retroviruses and Opportunistic Infections, researchers presented Phase III data showing that 77% of patients taking the 400 mg dose of raltegravir plus other antiretroviral drugs reached HIV viral loads below 400 copies, nearly twice as many compared with a placebo control group.
[edit] External links
- MK-0518 at Aidsmedscom
- Integrase Inhibitor Raltegravir (MK-0518) Doubles HIV Suppression in Treatment-Experienced Patients (Aidsmap 28 February 2007)
- RMK-0518 Abstract from CROI 2007
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507-22. [2]
